Last 12,550 KRW
Change Today -400.00 / -3.09%
Volume 238.5K
083790 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 1:29 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

crystalgenomics inc (083790) Snapshot

Open
12,950
Previous Close
12,950
Day High
13,050
Day Low
12,350
52 Week High
08/4/14 - 19,500
52 Week Low
11/14/14 - 10,250
Market Cap
283.6B
Average Volume 10 Days
262.1K
EPS TTM
-628.00
Shares Outstanding
22.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CRYSTALGENOMICS INC (083790)

Related News

No related news articles were found.

crystalgenomics inc (083790) Related Businessweek News

No Related Businessweek News Found

crystalgenomics inc (083790) Details

CrystalGenomics, Inc., a biopharmaceutical company, operates as a structural chemoproteiomics-based drug discovery and development company in South Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles. The company’s drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus that has completed Phase I studies in Europe, as well as is in Phase IIa study in the United States. CrystalGenomics, Inc. is based in Seongnam, South Korea.

crystalgenomics inc (083790) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

crystalgenomics inc (083790) Key Developments

CrystalGenomics Partners with Daewoong Pharmaceutical for Acelex Commercialization in Korea

CrystalGenomics, Inc. announced that it has signed a Sales and Marketing Agreement with Daewoong Pharmaceutical for the commercialization of Acelex (polmacoxib) in Korea. Under the terms of the agreement, Daewoong will secure exclusive rights in Korea to sell and market Acelex, a 2mg capsule novel NSAID developed by CrystalGenomics for the treatment of osteoarthritis. CrystalGenomics will receive an upfront payment and milestone payments from Daewoong and will share profit from sales of Acelex, which is expected to rapidly capture at least 10% of the arthritis market in Korea that is estimated to be worth more than KRW 500 billion per year. Osteoarthritis is quite common in Korea, affecting about 50% of the population aged 65 years or older of which the number of patients is growing at 18% per year due to aging and obesity.

CrystalGenomics Receives MFDS Approval for Acelex® (Polmacoxib)

CrystalGenomics, Inc. announced that it has received approval for Acelex® (polmacoxib) from the Korean Ministry of Food and Drug Safety (MFDS) for the treatment of osteoarthritis. Pre-commercialization will commence immediately and a commercial launch partner for the Korean market will be announced very shortly. Acelex is the first, tissue-specific once-a-day osteoarthritis drug with a novel mode of action that specifically targets affected joints to relieve pain and restore mobility, while simultaneously preserving the integrity and safety of the gastrointestinal and cardiovascular systems. The results from the Phase 3 study suggest that Acelex 2mg once-a-day provides more rapid onset of relief from the signs and symptoms of osteoarthritis in comparison to celecoxib 200mg once-a-day, without added safety risk. Acelex is expected to rapidly capture at least 10% of the arthritis market in Korea that is estimated to be worth more than KRW 500 billion per year as of 2013. Osteoarthritis is quite common in Korea, as it affects about 50% of the population aged 65 years or older. Moreover, the overall number of patients is growing rapidly due to an aging population coupled with an increasing prevalence of obesity.

CrystalGenomics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

CrystalGenomics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
083790:KS 12,550.00 KRW -400.00

083790 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.85 USD -0.03
Array BioPharma Inc $8.30 USD +0.335
Exelixis Inc $3.10 USD +0.17
Infinity Pharmaceuticals Inc $16.00 USD +0.80
Rigel Pharmaceuticals Inc $3.10 USD +0.105
View Industry Companies
 

Industry Analysis

083790

Industry Average

Valuation 083790 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.0x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRYSTALGENOMICS INC, please visit www.cgxinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.